中国儿童白血病协作组CCLG-ALL 2008方案治疗初诊儿童急性淋巴细胞白血病的结局:中国首个全国性前瞻性多中心研究
该研究为CCLG-ALL 2008前瞻性临床试验,纳入8个城市10家三级医院的2231例初诊儿童急性淋巴细胞白血病患者,按临床生物学特征及早期治疗反应分层治疗。全组5年总生存率85.3%、无事件生存率79.9%,完全缓解率94.1%;标危组5年无事件生存率87.9%;微小残留病监测组5年无事件生存率82.4%优于非监测组78.3%(P=.038)。
要点
- 全组2231例初诊儿童ALL患者,完全缓解2100例(94.1%),5年总生存率85.3%、无事件生存率79.9%。
- 标危组5年总生存率91.5%、无事件生存率87.9%、累积复发率9.7%。
- 微小残留病监测组5年无事件生存率82.4% vs 非监测组78.3%(P=.038),5年累积复发率10.7% vs 18.0%(P<.001)。
核心结论
- 研究结果表明,在中国开展大规模多中心儿童急性淋巴细胞白血病临床试验是可行的。
- 标危组减少剂量可获得较高的无事件生存率。
- 基于微小残留病的风险分层可能改善儿童急性淋巴细胞白血病的治疗结局。
研究设计与样本
- CCLG-ALL 2008是一项前瞻性临床试验,旨在通过中国首个全国性协作研究改善儿童急性淋巴细胞白血病的治疗结局。
- 共纳入来自8个城市10家三级医院的2231例患者。
- 患者根据临床生物学特征和早期治疗反应进行分层。
- 标危组和中危组采用改良BFM方案治疗,标危组在强化治疗阶段剂量减少25%-50%。
- 高危组接受更强化的维持治疗。
主要发现
- 2100例患者(94.1%)达到完全缓解。
- 全组5年总生存率估计为85.3%,无事件生存率估计为79.9%。
- 5年累积复发率为15.3%。
- 标危组5年总生存率91.5%、无事件生存率87.9%、累积复发率9.7%。
- 微小残留病组结局优于非微小残留病组:5年无事件生存率82.4% vs 78.3%(P=.038);5年累积复发率10.7% vs 18.0%(P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute lymphoblastic leukemia (ALL) is the most common malignancy among children. The trial Chinese Children Leukemia Group (CCLG)-ALL 2008 was a prospective clinical trial designed to improve treatment outcome of childhood ALL through the first nation-wide collaborative study in China. Totally 2231 patients were recruited from ten tertiary hospitals in eight cities. The patients were stratified according to clinical-biological characteristics and early treatment response. Standard risk (SR) and intermediate risk (IR) groups were treated with a modified BFM based protocol, and there was 25%-50% dose reduction during intensification phases in the SR group. Patients in high risk (HR) group received a more intensive maintenance treatment. Minimal residual disease (MRD) monitoring with treatment adjustment was performed in two hospitals (the MRD group). Complete remission (CR) was achieved in 2100 patients (94.1%). At five years, the estimate for overall survival (OS) and event-free survival (EFS) of the whole group was 85.3% and 79.9%, respectively. The cumulative incidence of relapse (CIR) was 15.3% at five years. The OS, EFS and CIR for the SR group were 91.5%, 87.9%, and 9.7%, respectively. The outcome of the MRD group is better than the non-MRD group (5y-EFS: 82.4% vs 78.3%, P = .038; 5y-CIR: 10.7% vs 18.0%, P < .001). Our results demonstrated that the large-scale multicenter trial for pediatric ALL was feasible in China. Dose reduction in the SR group could achieve high EFS. MRD-based risk stratification might improve the treatment outcome for childhood ALL.
引用
- Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China. Am J Hematol. 2018. PMID: 29675840. doi:10.1002/ajh.25124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。